Literature DB >> 16359526

Carboxypeptidase B2 gene polymorphisms and the risk of venous thromboembolism.

R Y L Zee, H H Hegener, P M Ridker.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16359526     DOI： 10.1111/j.1538-7836.2005.01665.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN： 1538-7836            Impact factor:   5.824


× No keyword cloud information.
  4 in total

1.  Sex-specific effect of CPB2 Ala147Thr but not Thr325Ile variants on the risk of venous thrombosis: A comprehensive meta-analysis.

Authors:  Nora Zwingerman; Alejandra Medina-Rivera; Irfahan Kassam; Michael D Wilson; Pierre-Emmanuel Morange; David-Alexandre Trégouët; France Gagnon
Journal:  PLoS One       Date:  2017-05-26       Impact factor: 3.240

Review 2.  Carboxypeptidase U (CPU, TAFIa, CPB2) in Thromboembolic Disease: What Do We Know Three Decades after Its Discovery?

Authors:  Karen Claesen; Joachim C Mertens; Dorien Leenaerts; Dirk Hendriks
Journal:  Int J Mol Sci       Date:  2021-01-17       Impact factor: 5.923

Review 3.  Thrombin Activatable Fibrinolysis Inhibitor (TAFI): An Updated Narrative Review.

Authors:  Machteld Sillen; Paul J Declerck
Journal:  Int J Mol Sci       Date:  2021-04-01       Impact factor: 5.923

4.  Systems-Pharmacology Dissection of Traditional Chinese Medicine Compound Saffron Formula Reveals Multi-scale Treatment Strategy for Cardiovascular Diseases.

Authors:  Jianling Liu; Jiexin Mu; Chunli Zheng; Xuetong Chen; Zihu Guo; Chao Huang; Yingxue Fu; Guihua Tian; Hongcai Shang; Yonghua Wang
Journal:  Sci Rep       Date:  2016-01-27       Impact factor: 4.379
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.